Green Thumb Industries' Q3 sales beat estimates despite an earnings miss, but pricing pressure and margin declines raise questions about its growth outlook.
Green Thumb Industries' Q3 sales beat estimates despite an earnings miss, but pricing pressure and margin declines raise questions about its growth outlook.
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of +12.50% and +1.79%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.